Elixirgen Therapeutics Gains FDA Orphan Drug Status for EXG-34217 to Treat Telomere Biology Disorders
Friday, February 21, 2025
Elixirgen Therapeutics, a biotechnology company focused on rare diseases, has received Orphan Drug Status from the U.S. Food and Drug Administration (FDA) for EXG-34217, a gene therapy for Telomere Biology Disorders (TBDs). The treatment is currently being evaluated in a Phase 1/2 trial (NCT04211714) for patients with TBDs and bone marrow failure. Recruitment is open for individuals aged 12 and above.
The FDA has also granted EXG-34217 Rare Paediatric Disease Status and Regenerative Medicine Advanced Therapy (RMAT) Status.
Orphan Drug Status is given to treatments for rare diseases and provides benefits such as tax credits, grants, waivers for certain administrative fees, and the possibility of seven years of market exclusivity after approval.
TBDs are rare genetic disorders caused by very short telomeres, the protective caps at the ends of chromosomes that shorten over time. Conditions like dyskeratosis congenita can lead to severe health issues, including bone marrow failure, by affecting hematopoietic stem cells' ability to produce blood cells. EXG-34217 is made from a patient’s own CD34+ stem cells, which have been modified to express ZSCAN4, a protein that helps lengthen telomeres and maintain genome stability without relying on telomerase. TBDs affect about 1 in 1 million people in the U.S.
Source: elixirgentx.com
